Cabaletta Bio: Curative Medicines For Autoimmunity [Seeking Alpha]
Cabaletta Bio, Inc. (CABA)
Company Research
Source: Seeking Alpha
SummaryCabaletta Bio is pioneering the use of CAAR-T cell therapies to potentially cure various autoimmune diseases.Autoimmunity is a large market, at least $100B, but only having standard-of-care medicines like steroids that lead to nasty side effects and Humira.There is an opportunity to bring technologies that have already been clinically validated in blood cancers by companies such as Kite and Juno to autoimmune diseases.Cabaletta is composed of leaders in cell therapies and autoimmunity with a first-mover advantage and a lead asset in Phase I trials with initial results expected to come out in late 2020.Cabaletta Bio (CABACAR-TB-cell mediated autoimmune diseaseThe company was founded out of UPenn. Theleadership teamNVSADAPThe company went public in the fall 2019. Since then, the stock price is down over 50% from its peak. This decline is mainly due to the potential effects of COVID-19 on clinical trials. This provides an opportunistic buying opportunity in an early-stage company
Show less
Read more
Impact Snapshot
Event Time:
CABA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CABA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CABA alerts
High impacting Cabaletta Bio, Inc. news events
Weekly update
A roundup of the hottest topics
CABA
News
- Cabaletta Bio Reports Third Quarter 2025 Financial Results and Provides Business Update [Yahoo! Finance]Yahoo! Finance
- Cabaletta Bio GAAP EPS of -$0.44 beats by $0.04 [Seeking Alpha]Seeking Alpha
- Cabaletta Bio Reports Third Quarter 2025 Financial Results and Provides Business UpdateGlobeNewswire
- Cabaletta Bio (CABA): Assessing Valuation After Promising Clinical Trial Results and Growing Investor Interest [Yahoo! Finance]Yahoo! Finance
- Cabaletta Bio to Participate in Upcoming Investor Conferences in November and DecemberGlobeNewswire
CABA
Earnings
- 11/10/25 - Beat
CABA
Sec Filings
- 11/14/25 - Form SCHEDULE
- 11/14/25 - Form SCHEDULE
- 11/14/25 - Form SCHEDULE
- CABA's page on the SEC website